TLX•prnewswire•
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
Summary
SAN FRANCISCO, Dec. 1, 2025 /PRNewswire/ -- Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit following a series of regulatory...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 1, 2025 by prnewswire